Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Squamous Cell CarcinomaEndometrial Transitional Cell CarcinomaEndometrial Undifferentiated CarcinomaMalignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmRecurrent Uterine Corpus Carcinoma
Interventions
DRUG

Nintedanib

Given PO

Trial Locations (59)

11794

Stony Brook University Medical Center, Stony Brook

19001

Abington Memorial Hospital, Abington

19096

Lankenau Medical Center, Wynnewood

19107

Thomas Jefferson University Hospital, Philadelphia

21204

Greater Baltimore Medical Center, Baltimore

21237

MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore

28025

Carolinas HealthCare System NorthEast, Concord

28203

Carolinas Medical Center/Levine Cancer Institute, Charlotte

31404

Memorial University Medical Center, Savannah

39216

University of Mississippi Medical Center, Jackson

43214

Riverside Methodist Hospital, Columbus

44060

Lake University Ireland Cancer Center, Mentor

44106

Case Western Reserve University, Cleveland

44109

MetroHealth Medical Center, Cleveland

44111

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland

44124

Hillcrest Hospital Cancer Center, Mayfield Heights

44195

Cleveland Clinic Foundation, Cleveland

44307

Akron General Medical Center, Akron

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

46260

Saint Vincent Oncology Center, Indianapolis

48060

Saint Joseph Mercy Port Huron, Port Huron

48106

Michigan Cancer Research Consortium NCORP, Ann Arbor

48154

Saint Mary Mercy Hospital, Livonia

48439

Genesys Regional Medical Center, Grand Blanc

48502

Hurley Medical Center, Flint

49001

Borgess Medical Center, Kalamazoo

49007

Bronson Methodist Hospital, Kalamazoo

West Michigan Cancer Center, Kalamazoo

49201

Allegiance Health, Jackson

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53792

University of Wisconsin Hospital and Clinics, Madison

54143

Bay Area Medical Center, Marinette

54221

Holy Family Memorial Hospital, Manitowoc

54301

Saint Vincent Hospital, Green Bay

54303

Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay

60201

NorthShore University HealthSystem-Evanston Hospital, Evanston

60521

Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

65804

Mercy Hospital Springfield, Springfield

65807

CoxHealth South Hospital, Springfield

68114

Nebraska Methodist Hospital, Omaha

73104

University of Oklahoma Health Sciences Center, Oklahoma City

74146

Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

80045

University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora

83706

Saint Alphonsus Cancer Care Center-Boise, Boise

89169

Women's Cancer Center of Nevada, Las Vegas

91505

Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank

98104

Pacific Gynecology Specialists, Seattle

98109

Fred Hutchinson Cancer Research Center, Seattle

Seattle Cancer Care Alliance, Seattle

98133

Northwest Hospital, Seattle

98195

University of Washington Medical Center, Seattle

06105

Smilow Cancer Hospital Care Center at Saint Francis, Hartford

48106-0995

Saint Joseph Mercy Hospital, Ann Arbor

02905

Women and Infants Hospital, Providence

98122-4307

Swedish Medical Center-First Hill, Seattle

54301-3526

Green Bay Oncology at Saint Vincent Hospital, Green Bay

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT01225887 - Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | Biotech Hunter | Biotech Hunter